期刊文献+

329例转移性乳腺癌的预后因素及生存分析 被引量:7

Prognostic Factors and Survival Analysis of 329 Cases of Metastasis Breast Cancer
下载PDF
导出
摘要 目的观察转移性乳腺癌患者的疗效及预后情况,分析影响转移性乳腺癌患者生存的预后因素。方法选取转移性乳腺癌患者329例进行回顾性研究。结果总生存率(OS)1年总生存率为62.9%,2年总生存率为41.9%,3年总生存率为25.8%及5年总生存率11.9%。接受治疗的患者中位生存时间为18.2个月,分别为:骨转移患者23.4个月,淋巴结转移患者31.3个月,肝转移患者17.6个月,肺转移患者15.3个月,脑转移患者7.2个月。通过单因素及多因素分析,获取了同生存获益相关的预后因素。结论对转移性乳腺癌生存有积极影响的独立因素包括:体力状况,年龄≤70岁以及没有内脏的转移。对于此类患者,在解救治疗中应采取较为积极的处理措施,争取更好的生存获益。 Objective To observe the overall survival of metastatic breast cancer patients,and to analyze the prognostic factors that influence the survival of these patients. Methods 329 patients with metastatic breast cancer were collected. Results(OS)overall survival 1-2-3- and 5 years were respectively 62. 9%,41. 9%,25. 8% and 11. 9%. The median survival of patients who received treatments was 18. 2 months. The data were respectively 23. 4 months in bone metastasis,31. 3 months in lymph node metastasis,17. 6 months in hepatic metastasis,15. 3 months in lung metastasis and 7. 2 months in brain metastasis. Prognostic factors affecting survial were collected from univariate analysis and multivariate analysis. Conclusion Positive prognostic factors for metastatic breast cancer including physical status,age≤70 years and absence of visceral metastasis,positive measweres,should be taken for these patients.
作者 张剑辉 张蒲容 李俊杰 于淼 张欣 ZHANG Jianhui;ZHANG Purong;LI Junjie(Sichuan Cancer Hospital,Chengdu,610041)
出处 《实用癌症杂志》 2018年第5期830-834,共5页 The Practical Journal of Cancer
关键词 乳腺癌 转移 预后因素 总生存 Metastatic breast cancer Prognostic factors Overall survival
  • 相关文献

参考文献3

二级参考文献36

  • 1Slamon D J, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science, 1987, 235 : 177-182. 被引量:1
  • 2Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344:783- 792. 被引量:1
  • 3Marry M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23: 4265 -4274. 被引量:1
  • 4Schaller G, Fuchs I, Gonsch T, et al. Phase Ⅱ study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol, 2007, 25:3246-3250. 被引量:1
  • 5Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 2009, 28:803-814. 被引量:1
  • 6Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells : activation of AXL. Cancer Res, 2009, 69:6871-6878. 被引量:1
  • 7Cancello G, Montagna E, D' Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res, 2008, 10 : R60. 被引量:1
  • 8yon Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2- positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Onco|, 2009, 27: 1999- 2006. 被引量:1
  • 9Extra JM, Antoine EC, Vincent-Salomon A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist, 2010, 15:799-809. 被引量:1
  • 10Gori S, Montemurro F, Spazzapan S, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol, 2012, 23:1436-1441. 被引量:1

共引文献21

同被引文献72

引证文献7

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部